RSV Vaccine Approved for Use by Pregnant Women to Protect NewbornsKSL.com | By Lois Collins WASHINGTON — For the first time, there's a vaccine for pregnant women to protect their babies against respiratory syncytial virus. The U.S. Food and Drug Administration this week approved Abrysvo for use at 32 to 36 weeks of gestation. The vaccine, made by Pfizer, will protect infants from birth to up to 6 months of age from severe lower respiratory disease symptoms because of RSV, the agency said in announcing the approval, though the efficacy wanes to about 69% by 6 months. "RSV is a common cause of illness in children and infants are among those at highest risk for severe disease, which can lead to hospitalization," said Dr. Peter Marks, director of the FDA Center for Biologics Evaluation and Research, in the news release. "This approval provides an option for health care providers and pregnant individuals to protect infants from this potentially life-threatening disease."… |
Join Our Free Email List
Click here to join
Want to hear the latest news on the home care and hospice industries in Colorado and receive information on upcoming events? Please complete this form and you'll be added to our free email list. If you'd like information on membership, please call us at 303-848-2521 or email [email protected].
Our Allied Members
